This review discusses the concept of privileged scaffolds in drug discovery, focusing on their role in creating effective compound libraries. Privileged scaffolds are molecular frameworks that have the potential to bind multiple targets, making them valuable for drug discovery. The authors highlight the importance of these scaffolds in improving the efficiency of drug discovery by enabling the creation of diverse and potent compound collections. The review outlines several examples of privileged scaffolds, including benzodiazepines, purines, and 2-arylindoles. These scaffolds have been shown to be effective in various biological applications, such as targeting G-protein-coupled receptors and kinases. The synthesis of these scaffolds involves a variety of chemical strategies, including combinatorial synthesis and diversity-oriented synthesis, which allow for the generation of large libraries of compounds with diverse structures. The authors also discuss the challenges in identifying new privileged scaffolds and suggest that future research should focus on exploring underutilized chemical spaces and leveraging computational methods to identify novel scaffolds. They emphasize the importance of considering both structural and functional properties of scaffolds in the design of effective drug candidates. The review concludes by highlighting the potential of privileged scaffolds in accelerating drug discovery and improving the success rate of therapeutic interventions. It underscores the need for continued research and innovation in the development of new and effective scaffolds for drug discovery.This review discusses the concept of privileged scaffolds in drug discovery, focusing on their role in creating effective compound libraries. Privileged scaffolds are molecular frameworks that have the potential to bind multiple targets, making them valuable for drug discovery. The authors highlight the importance of these scaffolds in improving the efficiency of drug discovery by enabling the creation of diverse and potent compound collections. The review outlines several examples of privileged scaffolds, including benzodiazepines, purines, and 2-arylindoles. These scaffolds have been shown to be effective in various biological applications, such as targeting G-protein-coupled receptors and kinases. The synthesis of these scaffolds involves a variety of chemical strategies, including combinatorial synthesis and diversity-oriented synthesis, which allow for the generation of large libraries of compounds with diverse structures. The authors also discuss the challenges in identifying new privileged scaffolds and suggest that future research should focus on exploring underutilized chemical spaces and leveraging computational methods to identify novel scaffolds. They emphasize the importance of considering both structural and functional properties of scaffolds in the design of effective drug candidates. The review concludes by highlighting the potential of privileged scaffolds in accelerating drug discovery and improving the success rate of therapeutic interventions. It underscores the need for continued research and innovation in the development of new and effective scaffolds for drug discovery.